JP7464528B2 - 多能性幹細胞からt細胞を入手するための新規な方法およびその使用 - Google Patents
多能性幹細胞からt細胞を入手するための新規な方法およびその使用 Download PDFInfo
- Publication number
- JP7464528B2 JP7464528B2 JP2020550615A JP2020550615A JP7464528B2 JP 7464528 B2 JP7464528 B2 JP 7464528B2 JP 2020550615 A JP2020550615 A JP 2020550615A JP 2020550615 A JP2020550615 A JP 2020550615A JP 7464528 B2 JP7464528 B2 JP 7464528B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- population
- tcrab
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 162
- 238000000034 method Methods 0.000 title claims description 121
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims description 70
- 210000004027 cell Anatomy 0.000 claims description 246
- 210000002242 embryoid body Anatomy 0.000 claims description 104
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 72
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 70
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 70
- 150000007523 nucleic acids Chemical group 0.000 claims description 62
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 56
- 102100039564 Leukosialin Human genes 0.000 claims description 55
- 239000013598 vector Substances 0.000 claims description 54
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 52
- 210000003289 regulatory T cell Anatomy 0.000 claims description 50
- 239000002609 medium Substances 0.000 claims description 41
- 239000003446 ligand Substances 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 26
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 22
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 22
- 238000012258 culturing Methods 0.000 claims description 21
- -1 Flt3-L Proteins 0.000 claims description 20
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 19
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 15
- 208000024908 graft versus host disease Diseases 0.000 claims description 15
- 206010052779 Transplant rejections Diseases 0.000 claims description 14
- 108010002586 Interleukin-7 Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 10
- 108010002386 Interleukin-3 Proteins 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 239000012679 serum free medium Substances 0.000 claims description 7
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 4
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 4
- 210000005236 CD8+ effector T cell Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 52
- 230000014509 gene expression Effects 0.000 description 48
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 44
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 39
- 230000004069 differentiation Effects 0.000 description 38
- 108010070047 Notch Receptors Proteins 0.000 description 34
- 102000005650 Notch Receptors Human genes 0.000 description 34
- 238000010361 transduction Methods 0.000 description 30
- 230000026683 transduction Effects 0.000 description 30
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 26
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 24
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 21
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000003102 growth factor Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 16
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 16
- 229940112869 bone morphogenetic protein Drugs 0.000 description 16
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 238000003501 co-culture Methods 0.000 description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 13
- 229930182816 L-glutamine Natural products 0.000 description 13
- 239000003797 essential amino acid Substances 0.000 description 13
- 235000020776 essential amino acid Nutrition 0.000 description 13
- 102100021592 Interleukin-7 Human genes 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 229940100994 interleukin-7 Drugs 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 230000007170 pathology Effects 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 230000008938 immune dysregulation Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 102100039064 Interleukin-3 Human genes 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 108700014844 flt3 ligand Proteins 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 6
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 6
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 6
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 238000003559 RNA-seq method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 101100069853 Caenorhabditis elegans hil-3 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 108010005832 Leukosialin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 108010076089 accutase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003409 anti-rejection Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 102000046148 human BMP4 Human genes 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 101100454433 Biomphalaria glabrata BG01 gene Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 description 1
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100036462 Delta-like protein 1 Human genes 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 101150027879 FOXP3 gene Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 101710088098 Forkhead box protein P3 Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101150083678 IL2 gene Proteins 0.000 description 1
- 108010013958 Ikaros Transcription Factor Proteins 0.000 description 1
- 102000017182 Ikaros Transcription Factor Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000608941 Mus musculus Leukosialin Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108010061228 Sialomucins Proteins 0.000 description 1
- 102000012010 Sialomucins Human genes 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
a)少なくとも5%のCD34+CD43+細胞を含む胚様体を入手できる条件下で多能性幹細胞を培養する段階と;
b)上記胚様体を分離する段階と;
c)上記分離した胚様体を、好ましくは少なくとも1つのNotchリガンドを発現する細胞との共培養で、少なくとも1つのNotchリガンドとともに培養する段階と;
d)段階c)中に、好ましくは細胞集団の少なくとも15%がCD43-表現型を示す場合に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含む、方法である。
本発明では、「約」という用語は、ある数値が、測定装置の使用に関連する許容誤差、その数値を求めるのに用いる方法、または試験する集団内の細胞間および集団間に存在し得る変動に特有の変動を含むことを表すのに使用される。したがって、一実施形態では、ある数値の前にある「約」という用語は、この数値の±10%に対応する。
本発明者らは、多能性幹細胞からTリンパ球集団を入手する新たな方法を発見した。より具体的には、本発明の方法に従って入手されるT細胞集団は、CD8+CD3+TCRab+Foxp3+および/またはCD4+CD3+TCRab+Foxp3+Treg細胞、(Foxp3-)CD8+および/またはCD4+Teff細胞、ならびにCD4-CD8-CD3+TCRab+T細胞を含み得る。
a)少なくとも5%のCD34+CD43+細胞を含む胚様体を入手できる条件下で多能性幹細胞を培養する段階と;
b)上記胚様体を分離する段階と;
c)上記分離した胚様体を、好ましくは少なくとも1つのNotchリガンドを発現する細胞との共培養で、少なくとも1つのNotchリガンドとともに培養する段階と;
d)任意選択で、好ましくは細胞集団の少なくとも15%がCD43-表現型を示す場合に、段階c)中に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階;
を含み、上記多能性幹細胞がヒト胚性幹細胞ではない、方法に関する。
a)少なくとも5%のCD34+CD43+細胞を含む胚様体を入手できる条件下で多能性幹細胞を培養する段階と;
b)上記胚様体を分離する段階と;
c)上記分離した胚様体を、好ましくは少なくとも1つのNotchリガンドを発現する細胞との共培養で、少なくとも1つのNotchリガンドとともに培養する段階と;
d)好ましくは細胞集団の少なくとも15%がCD43-表現型を示す場合に、段階c)中に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含む、方法に関する。
a)多能性幹細胞を、BMP、FGF2、VEGF、SCF、Flt3-L、およびIL-3を含み、造血細胞の増殖に適した無血清培地中で、少なくとも5%のCD34+CD43+細胞を含む胚様体を入手できる条件下で、少なくとも9日間培養する段階と;
b)上記胚様体を分離する段階と;
c)上記分離した胚様体を、SCF、Flt3-L、およびIL-7を含む分化培地中で、少なくとも15日間、好ましくは少なくとも1つのNotchリガンドを発現する細胞との共培養で、少なくとも1つのNotchリガンドとともに培養して、上記T細胞集団を入手する段階と;
d)段階c)中に、好ましくは細胞集団の少なくとも15%がCD43-表現型を示す場合に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの第8日(Dd8)~第12(Dd12)日での導入を、少なくとも1つの細胞で実施する段階
を含む。
(a)造血幹細胞を入手できる条件下で多能性幹細胞を培養する段階と;
b)上記造血幹細胞を、それらをT細胞に分化させる条件下に置く段階と;
c)任意選択で、または同時に、段階b)中に、目的とする核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含む、方法に関する。
a)造血幹細胞を入手できる条件下で多能性幹細胞を培養する段階と;
b)上記造血幹細胞を、それらをT細胞に分化させる条件下に置く段階と;
c)段階b)中に、目的とする核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含む、方法に関する。
a)少なくとも5%のCD34+CD43+細胞を含む胚様体を入手できる条件下で多能性幹細胞を培養する段階と;
b)上記胚様体を分離する段階と;
c)上記分離した胚様体を、好ましくは少なくとも15日間、少なくとも1つのNotchリガンドの存在下に置く段階と;
d)任意選択で、または同時に、段階c)中に、好ましくは第8日(Dd8)~第12日(Dd12)に、好ましくは細胞集団の少なくとも15%がCD43-表現型を示す場合に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含む。
a)少なくとも5%のCD34+CD43+細胞を含む胚様体を入手できる条件下で多能性幹細胞を培養する段階と;
b)上記胚様体を分離する段階と;
c)上記分離した胚様体を、好ましくは少なくとも15日間、少なくとも1つのNotchリガンドの存在下に置く段階と;
d)段階c)中に、好ましくは第8日(Dd8)~第12日(Dd12)、好ましくは第9日(Dd9)~第11日(Dd11)に、好ましくは細胞集団の少なくとも15%がCD43-表現型を示す場合に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含む。
a)造血幹細胞を入手できる条件下で多能性幹細胞を培養する段階であって、胚様体の発生、次いで上記胚様体を分離することを含む、段階と;
b)造血幹細胞を含む上記分離した胚様体を、好ましくは少なくとも15日間、例えば少なくとも1つのNotchリガンドを発現する細胞との共培養で、少なくとも1つのNotchリガンドの存在下に置いて、それらをT細胞に分化させる段階と;
c)任意選択で、または同時に、段階b)中に、好ましくは第8日(Dd8)~第12日(Dd12)に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含み、細胞を、細胞集団の少なくとも5%がCD34+CD43+表現型を示す場合に段階b)に従い少なくとも1つのNotchリガンドの存在下に置き、好ましくは段階c)で計画されるベクターの導入を、細胞集団の少なくとも15%がCD43-表現型を示す場合に実施する、方法に関する。
a)造血幹細胞を入手できる条件下で多能性幹細胞を培養する段階であって、胚様体の発生、次いで上記胚様体を分離することを含む、段階と;
b)造血幹細胞を含む上記分離した胚様体を、好ましくは少なくとも15日間、例えば少なくとも1つのNotchリガンドを発現する細胞との共培養で、少なくとも1つのNotchリガンドの存在下に置いて、それらをT細胞に分化させる段階と;
c)段階b)中に、好ましくは第8日(Dd8)~第12日(Dd12)、好ましくは第9日(Dd9)~第11日(Dd11)に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含み、好ましくは、細胞を、細胞集団の少なくとも15%がCD34+CD43+表現型を示す場合に段階b)に従い少なくとも1つのNotchリガンドの存在下に置き、好ましくは、段階c)で計画されるベクターの導入を、細胞集団の少なくとも15%がCD43-表現型を示す場合に実施する、方法に関する。
a)造血幹細胞を入手できる条件下で多能性幹細胞を培養する段階であって、胚様体の発生、次いで上記胚様体を分離することを含む、段階と;
b)造血幹細胞を含む上記分離した胚様体を、好ましくは少なくとも15日間、例えば少なくとも1つのNotchリガンドを発現する細胞との共培養で、少なくとも1つのNotchリガンドの存在下に置いて、それらをT細胞に分化させる段階と;
c)段階b)中に、好ましくは第8日(Dd8)~第12日(Dd12)に、Foxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、少なくとも1つの細胞で実施する段階
を含み、細胞を、細胞集団の少なくとも5%、好ましくは少なくとも10%、好ましくは少なくとも15%がCD34+CD43+表現型を示す場合に段階b)に従い少なくとも1つのNotchリガンドの存在下に置き、段階c)で計画されるベクターの導入を、細胞集団の少なくとも15%、好ましくは少なくとも20%がCD43-表現型を示す場合に実施することを特徴とする、方法に関する。
実施例1(本発明の方法の実施を説明する参照例)
実験プロトコル
フランスの法的ガイドラインおよび地方施設の倫理委員会に従い研究プロトコルを実施した。
ヒト多能性幹細胞の未分化コロニー(市販のhES WA09(WiCell)系)を、DMEM/F12、20%のKSR(「ノックアウト血清リプレースメント」)血清、1%のL-グルタミン、1%の非必須アミノ酸、0.1%の2-メルカプトエタノール、10ng/mLのFGF2(線維芽細胞増殖因子)(図1、「段階0」)を含む多能性幹細胞用の培地中で、マウス胚線維芽細胞(「MEF」)上の培養にて維持した。5~6日毎に継代を実施する。
ヒト多能性幹細胞を造血細胞に分化させるため、未分化コロニーをディスパーゼ(1U/mL)で10分間処理し、低接着プレートに移して、胚様体を形成させた。
造血幹細胞を含むD7、D8、およびD9での胚様体を、Accutase(登録商標)で10分間処理することにより分離し、存在するマーカーを、フローサイトメトリーにより分析した。
D9に入手した胚様体を、Accutase(登録商標)で10分間処理することにより分離した。このようにして単離した細胞を、OP9-DLL1細胞の単層上に播種して、リンパ系Tに分化させた。この分化を可能にする培地「中間OP9」(図1、「段階II」)は、20%のFBS、1%のL-グルタミン、1%の非必須アミノ酸、0.1%の2-メルカプトエタノール、100U/mLのペニシリン、100ng/mLのストレプトマイシン、および50μg/mLのアスコルビン酸を含み、SCF(10ng/mL)、IL-7(5ng/mL)、およびFlt3L(5ng/mL)が添加されたα-MEMを含む。2日毎に培地の半分を入れ替え、5日毎に細胞を新たなOP9-DLL1単層に移した(図1、文字「e」)。
構築物pMSCV-ヒトFoxp3-EF1-GFP-T2A-Puro(FOXP3GFP)を保有するレンチウイルス9μgと、パッケージングプラスミドpsPAX2 8μgと、プラスミドpMD2G 4μgとを含むDNAプラスミドを作製した。塩化カルシウム法を用いてそれをHEK293T細胞にトランスフェクトした。トランスフェクションの42~66時間後、HEK293T細胞の上清中のレンチウイルス粒子を収集した。力価測定のために、Jurkat細胞100,000個を培養し、10μL~0.078μLの範囲にわたるウイルスの半分の段階希釈物を混入させた。3日後、細胞を回収し、GFP(緑色蛍光タンパク質)の蛍光をフローサイトメトリーにより分析した。
Dd0、Dd5、Dd10、およびDd15(それぞれOP9-DLL1単層上での培養開始後第5日、第10日、および第15日)の細胞を回収し、遠心分離し、サイトカインを含むOP9培地500μL中、37℃で40分間、1細胞当たりウイルス粒子20個の感染多重度(MOI)にてFOXP3GFPレンチウイルスで形質導入した。形質導入後、細胞を、サイトカインを含むOP9培地2mL中の新たなOP9-DLL1単層に播種した。
フェノタイピングおよびフローサイトメトリー分析のために、以下のコンジュゲート抗体:CD34-PeCY7、CD43-APC、KDR(CD309)-PE、CD7-PeCy5、CD5-BV510、CD3-APCCy7、TCRab-APC、CD4-BV605、CD8a-PE、およびCD8b-PeCy7(ThermoFisher社)を使用した。いずれの抗体も20倍希釈で使用した。死細胞を、DAPIで標識することにより全ての実験で分析から除外した。蛍光を、LSR IIIまたはCanto IIサイトメーター(BD Biosciences社)で測定し、FLOWJOソフトウェア(FlowJo社、アシュランド、米国)で分析した。
RNeasy-Microキット(Qiagen社)を用いて全RNAを単離し、次いで、これを用いてRNAシーケンシングを実施した。RNAシーケンシングのための3‘DGEプロトコルは、Picardaら(2017)に記載されているものである。
図2は、7日間にわたる胚様体培養(本発明の方法の段階1)後、細胞の約40%がCD34+を発現することを示す。第7日~第9日に、集団中のCD34+細胞の割合は安定なままであり、CD43+の割合は増加している。胚様体発生の第9日に、CD34+細胞は、より高いレベルのRunx3、Ikaros、およびIL-7Rなどの転写因子またはリンパ系分化のキー分子を発現する(結果は不掲載)。
市販のhES WA09幹細胞(WiCell)から実施例1に記載した造血幹細胞を入手するプロトコル(段階I)を、hES WA01細胞(WiCell)、hiPS T04(CRTI/PFiPSC Nantes)、hiPS LON80(PFiPSC Nantes)から実施した。
Baine I,Basu S,Ames R,Sellers R,Macian F.(2013)Helios induces epigenetic silencing of Il2 gene expression in regulatory T cells.J Immunol.190(3):1008-1016.
Bonini C,Mondino A.(2015)Adoptive T-cell therapy for cancer:The era of engineered T cells.Eur J Immunol.45(9):2457-69.
Cavazzana-Calvo Marina,Six Emmanuelle,Andre-Schmutz Isabelle,Coulombel Laure.(2007)Hematopoiese humaine:des cellules CD34 aux lymphocytes T.Med Sci:23(2):151-160.
Chang CW,Lai YS,Lamb LS Jr,Townes TM.(2014)Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells.PLoS One.9(5):e97335.
Chung Y,Klimanskaya I,Becker S,Li T,Maserati M,Lu SJ,Zdravkovic T,Ilic D,Genbacev O,Fisher S,Krtolica A,Lanza R.(2008)Human embryonic stem cell lines generated without embryo destruction.Cell Stem Cell.2(2):113-7.
Gill S,June CH.(2015)Going viral:chimeric antigen receptor T-cell therapy for hematological malignancies.Immunol Rev.263(1):68-89.
Haque Rizwanul,Lei Fengyang,Xiong Xiaofang,et al.(2012)Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity.The Journal of Immunology,189(3):1228-1236.
Haque,Mohammad et al.(2016)“Development of Stem Cell-Derived Antigen-Specific Regulatory T Cells Against Autoimmunity.” Journal of visualized experiments:JoVE 117:10.3791/54720.
Holmes R,Zuniga-Pflucker JC.(2009)The OP9-DL1 system:generation of T-lymphocytes from embryonic or hematopoietic stem cells in vitro.Cold Spring Harb Protoc.Feb;2009(2):pdb.prot5156.
Jensen MC,Riddell SR.(2015)Designing chimeric antigen receptors to effectively and safely target tumors.Curr Opin Immunol.33:9-15.
Kato Shingo,Jay A Berzofsky,Masaki Terabe.(2018)“Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity.” Frontiers in Immunology 9:314.
Lei F,Haque R,Weiler L,Vrana KE,Song J.(2009)T lineage differentiation from induced pluripotent stem cells.Cell Immunol.260(1):1-5.
MacDonald KG,Hoeppli RE,Huang Q,Gillies J,Luciani DS,Orban PC,Broady R,Levings MK.(2016)Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.J Clin Invest.126(4):1413-24
Passerini,Laura,Rosa Bacchetta.(2017)“Forkhead-Box-P3 Gene Transfer in Human CD4+T Conventional Cells for the Generation of Stable and Efficient Regulatory T Cells,Suitable for Immune Modulatory Therapy.” Frontiers in Immunology 8:1282.
Picarda E,Bezie S,Boucault L,Autrusseau E,Kilens S,Meistermann D,Martinet B,Daguin V,Donnart A,Charpentier E,David L,Anegon I,Guillonneau C.(2017)Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.JCI Insight.2(3):e90088.
Srivastava S,Riddell SR.(2015)Engineering CAR-T cells:Design concepts.Trends Immunol.36(8):494-502.
Claims (15)
- 多能性幹細胞から調節性T細胞(Treg)を含むT細胞の集団を入手するための方法であって、以下の段階:
a)少なくとも5%のCD34+CD43+細胞を含む胚様体を入手することを可能にする条件下で多能性幹細胞を培養する段階と;
b)前記胚様体を分離する段階と;
c)少なくとも1つのNotchリガンドとともに前記分離された胚様体を培養する段階と;
d)少なくとも1つの細胞でFoxp3をコードする少なくとも1つの核酸配列を含むベクターの導入を、段階c)中に、段階c)の第8日(Dd8)および第12日(Dd12)の間で実施する段階
を含む、方法。 - 段階a)で得られた前記胚様体が、少なくとも15%のCD34+CD43+細胞を含む、請求項1に記載の方法。
- 段階a)を少なくとも9日間実施する、請求項1または2に記載の方法。
- 段階a)を、BMP、FGF2、VEGF、SCF、Flt3-L、および/またはIL-3を含む無血清培地中で実施する、請求項1~3のいずれか1項に記載の方法。
- 段階b)の終了時に得られた、前記分離された胚様体を、段階c)で、少なくとも15日間、SCF、Flt3-Lおよび/またはIL-7を含む培地中で培養する、請求項1~4のいずれか1項に記載の方法。
- 段階d)の前記ベクターが、レトロウイルスである、請求項1~5のいずれか1項に記載の方法。
- 段階d)の前記ベクターの前記核酸配列が、目的のさらなる核酸配列を含む、請求項1~6のいずれか1項に記載の方法。
- 前記目的のさらなる核酸配列が、キメラ抗原受容体(CAR)、Mcl-1、Bcl-xL、およびHeliosをコードする核酸から選択される、請求項7に記載の方法。
- 前記多能性幹細胞が、ヒト人工多能性幹細胞またはヒト胚性幹細胞である、請求項1~8のいずれか1項に記載の方法。
- 前記方法により得られたT細胞の集団が、調節性T細胞(Treg)、エフェクターT細胞(Teff)、およびCD4-CD8-CD3+TCRab+T細胞を含む、請求項1~9のいずれか1項に記載の方法。
- 調節性T細胞(Treg)、エフェクターT細胞(Teff)、およびCD4-CD8-CD3+TCRab+T細胞から選択される細胞集団を単離する追加の段階を含む、請求項1~10のいずれか1項に記載の方法。
- 前記方法により得られたT細胞の集団が、CD8+CD3+TCRab+Foxp3+Treg細胞およびCD4+CD3+TCRab+Foxp3+Treg細胞、CD8+エフェクターT細胞およびCD4+エフェクターT細胞、ならびにCD4-CD8-CD3+TCRab+T細胞を含む、請求項1~11のいずれか1項に記載の方法。
- 請求項1~12のいずれか1項に記載の方法により入手されたT細胞の集団であって、CD8+CD3+TCRab+Foxp3+Treg細胞およびCD4+CD3+TCRab+Foxp3+Treg細胞、CD8+エフェクターT細胞およびCD4+エフェクターT細胞、ならびにCD4-CD8-CD3+TCRab+T細胞を含むことを特徴とする、T細胞の集団。
- 薬物としての使用のための、請求項13に記載のT細胞の集団および薬学的に許容可能なキャリアを含む、医薬組成物。
- それを必要とする患者における、感染症、自己免疫疾患、炎症性疾患、癌、アレルギー、移植片拒絶反応、または移植片対宿主病の治療における使用のための、請求項13に記載のT細胞の集団および薬学的に許容可能なキャリアを含む、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1852531 | 2018-03-23 | ||
FR1852531A FR3079239A1 (fr) | 2018-03-23 | 2018-03-23 | Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations |
PCT/FR2019/050667 WO2019180394A1 (fr) | 2018-03-23 | 2019-03-22 | Nouvelle méthode d'obtention de cellules t à partir de cellules souches pluripotentes, et leurs utilisations |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021518130A JP2021518130A (ja) | 2021-08-02 |
JPWO2019180394A5 JPWO2019180394A5 (ja) | 2022-03-03 |
JP7464528B2 true JP7464528B2 (ja) | 2024-04-09 |
Family
ID=63557539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020550615A Active JP7464528B2 (ja) | 2018-03-23 | 2019-03-22 | 多能性幹細胞からt細胞を入手するための新規な方法およびその使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210002612A1 (ja) |
EP (1) | EP3768828A1 (ja) |
JP (1) | JP7464528B2 (ja) |
FR (1) | FR3079239A1 (ja) |
WO (1) | WO2019180394A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114710958A (zh) * | 2019-11-08 | 2022-07-05 | 桑格摩生物治疗股份有限公司 | 工程化的调节t细胞的产生 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017100403A1 (en) | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1784481A1 (en) | 2004-08-25 | 2007-05-16 | Technion Research And Development Foundation, Ltd. | Methods of generating embryoid bodies using three dimensional scaffolds |
US8772028B2 (en) * | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
DK2981607T3 (da) * | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller |
WO2014180943A1 (en) | 2013-05-08 | 2014-11-13 | Vib Vzw | Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders |
-
2018
- 2018-03-23 FR FR1852531A patent/FR3079239A1/fr active Pending
-
2019
- 2019-03-22 US US16/982,881 patent/US20210002612A1/en active Pending
- 2019-03-22 JP JP2020550615A patent/JP7464528B2/ja active Active
- 2019-03-22 EP EP19718442.7A patent/EP3768828A1/fr active Pending
- 2019-03-22 WO PCT/FR2019/050667 patent/WO2019180394A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017100403A1 (en) | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
Non-Patent Citations (1)
Title |
---|
J. Immunol., 2012, Vol.189, No. 3, pp. 1228-1236 |
Also Published As
Publication number | Publication date |
---|---|
EP3768828A1 (fr) | 2021-01-27 |
US20210002612A1 (en) | 2021-01-07 |
FR3079239A1 (fr) | 2019-09-27 |
WO2019180394A1 (fr) | 2019-09-26 |
JP2021518130A (ja) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022163165A (ja) | 抗原特異的t細胞の製造方法 | |
JP7402211B2 (ja) | 幹細胞からt細胞を作製する方法および該t細胞を用いた免疫療法的方法 | |
Williams et al. | Generation of lytic natural killer 1.1+, Ly-49− cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates | |
Woll et al. | Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity | |
CA2826386C (en) | Hematopoietic precursor cell production by programming | |
Pulecio et al. | Conversion of human fibroblasts into monocyte-like progenitor cells | |
RU2691062C2 (ru) | Перепрограммирование эндотелия человека в гемопоэтических предшественников множественных линий дифференцировки с использованием определенных факторов | |
EP2331675B1 (en) | Markers of induced pluripotent stem cells | |
WO2012043651A1 (ja) | ミエロイド系血液細胞の製造方法 | |
US11401508B2 (en) | Methods for isolating human cardiac ventricular progenitor cells | |
US20220306988A1 (en) | Induction of arterial-type of hemogenic endothelium (ahe) and enhancement of t cell production from pscs through overexpression of ets factors or modulating mapk/erk signalling pathways | |
Li et al. | Targeted disruption of TCF12 reveals HEB as essential in human mesodermal specification and hematopoiesis | |
WO2016010155A1 (ja) | 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法 | |
CN114269904A (zh) | 由RAG失活的iPSC产生T细胞 | |
JP2019528057A (ja) | インビボで血管形成能を有する中胚葉細胞および/または血管内皮コロニー形成細胞様細胞を作製する方法 | |
JP2023540212A (ja) | ヒト卵黄嚢様造血細胞を生成するための組成物および方法 | |
JP6275646B2 (ja) | Mait様細胞およびその作製方法 | |
CN114364790A (zh) | T细胞的产生方法 | |
JP7464528B2 (ja) | 多能性幹細胞からt細胞を入手するための新規な方法およびその使用 | |
US20100189697A1 (en) | Cardiac-specific progenitor cells | |
Bae et al. | Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma | |
Boonkaew et al. | Efficient generation of endothelial cells from induced pluripotent stem cells derived from a patient with peripheral arterial disease | |
JP7385230B2 (ja) | 移植用培養細胞または培養組織の調製方法 | |
Eslami-Arshaghi et al. | Lymphoid lineage differentiation potential of mouse nuclear transfer embryonic stem cells | |
KUMAR | Locus-specific isolation of the Nanog chromatin identifies regulators relevant to pluripotency of mouse embryonic stem cells and reprogramming of somatic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220221 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230626 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20230626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231010 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240328 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7464528 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |